• Ocugen won provisional approval, priority designation in The Bahamas for OCU400 modifier gene therapy in retinitis pigmentosa.
• Regulator LARTA Board put the program on an expedited pathway toward full approval.
• Company plans expanded access supply, targeting first patient dosing within 90 days of full approval.
• OCU400 remains in Phase 3, with topline data expected in 1Q 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250702PRIMZONEFULLFEED9833839) on September 25, 2026, and is solely responsible for the information contained therein.